Noticeably, a latest study revealed that gut microbial metabolites influence osteoarthritis progression and intestinal farnesoid X receptor is a viable therapeutic target to ameliorate osteoarthritis by increasing intestinal L cell‐secreted glucagon‐like peptide 1, which uncovered the existence of a functional and targetable gut‐joint axis in human [12]. The gene discussed is NR1H4; the disease is osteoarthritis.